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ABSTRACT
◥
Purpose: In EGFR-mutated metastatic non–small cell lung can-
cer (NSCLC), outcomes from EGFR tyrosine kinase inhibitors have
differed historically by mutation type present, with lower benefit
reported in patients with ex21L858R versus ex19del mutations. We
investigated if EGFR-activating mutation subtypes impact treat-
ment outcomes in the phase III RELAY study. Associations between
EGFR mutation type and preexisting co-occurring and treatment-
emergent genetic alterations were also explored.
Materials and Methods: Patients with metastatic NSCLC, an
EGFR ex19del or ex21L858R mutation, and no central nervous
systemmetastases were randomized (1:1) to erlotinib (150 mg/day)
with either ramucirumab (10 mg/kg; RAMþERL) or placebo
(PBOþERL), every 2weeks, until RECIST v1.1–defined progression
or unacceptable toxicity. The primary endpoint was progression-
free survival (PFS). Secondary and exploratory endpoints includ-
ed overall response rate (ORR), duration of response (DOR),
PFS2, time-to-chemotherapy (TTCT), safety, and next-generation
sequencing analyses.
Results: Patients with ex19del and ex21L858R mutations had
similar clinical characteristics and comutational profiles. One-year
PFS rates for ex19del patients were 74% for RAMþERL versus 54%
for PBOþERL; for ex21L858R rates were 70% (RAMþERL) versus
47% (PBOþERL). Similar treatment benefits (ORR, DOR, PFS2,
and TTCT) were observed in RAMþERL–treated patients with
ex19del and ex21L858R. Baseline TP53 comutation was associated
with superior outcomes for RAMþERL in both ex19del and
ex21L858R subgroups. EGFR T790M mutation rate at progression
was similar between treatment arms and by mutation type.
Conclusions: RAMþERL provided significant clinical benefit
for both EGFR ex19del and ex21L858R NSCLC, supporting
this regimen as suitable for patients with either of these EGFR
mutation types.
Introduction
Non–small cell lung cancer (NSCLC) is a molecularly heteroge-
neous disease. Approximately 40% to 60% of East Asian patients
and 10% to 20% of Caucasian patients with NSCLC harbor a somatic
driver mutation in the EGFR gene (EGFRm; refs. 1, 2). Approximately
90% of EGFR-activating mutations involve deletions in exon 19
(ex19del) or a substitutionmutation in exon 21, specifically Leu858Arg
(ex21L858R; refs. 1, 3, 4). Although ex19del constitutes nearly 50%
and ex21L858R 40% of EGFR-activating mutations, variation in these
rates is observed between regions (1, 2). Ex21L858R is more prevalent
in Asian countries, particularly in Japan (5, 6).
EGFR-activating mutations are also a major predictive factor
for response to small-molecule EGFR tyrosine kinase inhibitor (TKI)
therapies. However, the degree of benefitmay differ based on theEGFR
mutation type, which has been shown to be an independent prognostic
marker (7, 8). Indeed, although both ex19del and ex21L858R muta-
tions benefit from EGFR-TKI treatment, subgroup analyses of several
landmark studies in EGFRm NSCLC indicate that patients with
ex21L858R derive more modest benefit with EGFR-TKI monotherapy
than patients with ex19del, as represented by its lower median
progression-free survival (PFS), smaller delta PFS, and higher PFS
HR (Table 1). The difference in PFS outcomes between ex19del and
ex21L858R is independent of EGFR-TKI generation used and is
observed with first-, second-, and third-generation EGFR-TKIs. As
treatment benefit in a given trial can be difficult to understand by
analyzing results using a single measure of PFS, the totality of PFS data
should be considered. Treatment benefit is most reflectively reported
using a combination of various absolute (median and delta PFS, and
1-year PFS rates) and relative (HR) PFS measures, which have
complementary roles in fully assessing the results of comparative
time-to-event analyses and together provide the most complete
insights into the different outcomes between ex19del and
ex21L858R (9–11). Meta-analyses and real-world evidence studies
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have provided further evidence for worse PFS outcomes and lower
response rates after EGFR-TKI therapy with ex21L858R compared
with ex19del (12–14). The different prognostic and predictive roles for
ex19del and ex21L858R have led to the widespread acceptance of these
mutations as an essential stratification factor in EGFRm NSCLC
clinical trials and thereby enhanced the design and interpretation of
these studies (13).
The potential to further improve patient outcomes by combining
an EGFR-TKI with an antiangiogenesis agent is supported by
strong preclinical and, more recently, clinical trial evidence (15–20).
However, there is a paucity of published literature on how dual
EGFR/VEGF pathway inhibition impacts outcomes by EGFR muta-
tion subtypes. In the randomized phase III RELAY trial for the first-
line treatment of EGFRm NSCLC, ramucirumab plus erlotinib
(RAMþERL) showed a consistent PFS treatment benefit compared
with placebo plus erlotinib (PBOþERL) among patients with
ex19del or ex21L858R (19), with similar median PFS, delta PFS
improvement, and HRs (Table 1), and a clear and early separation
of Kaplan–Meier PFS curves for both ex19del and ex21L858R
patients. With a median PFS of 19.4 months and an absolute PFS
improvement of 8.2 months versus single-agent EGFR-TKI, these
are among the best reported outcomes to date for a subgroup of
patients with ex21L858R, albeit in a population without central
nervous system (CNS) metastases.
As noted above, it is important to explore the context specificity
of EGFR mutation types to different therapeutic strategies. To
address this, we explored more comprehensively if the EGFR-
activating mutation subtypes impact treatment outcomes in
RELAY. In addition, potential associations between EGFRmutation
type and baseline characteristics, patterns of progression, treatment
patterns post–RELAY study treatment discontinuation, and pre-
existing co-occurring and treatment-emergent genetic alterations
were explored.
Materials and Methods
Study design and patients
Study design and patient eligibility were detailed previously (19).
Briefly, RELAY is a global, double-blind, placebo-controlled, random-
ized phase III study that enrolled patients with untreated metastatic
NSCLC with an EGFR ex19del or ex21L858R mutation as tested
locally. Random assignment was stratified according to EGFR muta-
tion subtype (ex19del vs. ex21L858R), local EGFR testing method
(therascreen/cobas vs. other PCR/sequencing-based methods), sex
(male vs. female), and region (East Asia vs. other). Randomized
patients (1:1) received either intravenous ramucirumab (10 mg/kg)
or matching placebo every 2 weeks, with erlotinib (150 mg oral) daily.
Study treatment continued until radiographic progression as assessed
by the investigator according to RECIST v1.1, unacceptable toxicity,
withdrawal of consent, noncompliance, or investigator decision.Use of
subsequent treatment was at the discretion of the investigator. The trial
adhered to the Declaration of Helsinki, the International Council for
Harmonisation Guideline for Good Clinical Practice, and applicable
local regulations. All patients provided written informed consent. The
trial is registered at ClinicalTrials.gov (identifier: NCT02411448).
Assessments
Tumor assessments were conducted using RECIST v1.1 at baseline,
every 6 weeks for 72 weeks, every 12 weeks thereafter until disease
progression or unacceptable toxicity, and at the 30-day follow-up visit.
Adverse events (AE) were assessed at every cycle and graded according
to the National Cancer Institute Common Terminology Criteria for
Adverse Events (v4.0).
Confirmatory central testing for ex19del and ex21L858R was con-
ducted on archival tissue samples collected at baseline and using the
commercial therascreen assay. Central testing did not inform eligibility
or study enrollment. Plasma samples were prospectively collected at
baseline, Day 1 Cycle 4, and at the 30-day post–study treatment
discontinuation follow-up visit, and were evaluated with Guardant360
next-generation sequencing (NGS; Guardant Health).
Analysis populations and study endpoints
Efficacy analyses were conducted in the population of randomly
assigned patients. Safety analyses were evaluated in patients who
received at least one dose of study drug. NGS analyses were conducted
in patients with valid baseline and/or 30-day follow-up samples
depending on whether baseline, treatment-emergent, or post-
progression follow-up mutation profiles were being investigated.
The primary endpoint was PFS (investigator-assessed). Secondary
endpoints included safety and tolerability, response rates, duration of
response (DOR), and interim overall survival (iOS). Prespecified PFS2
and post hoc analyses of patterns of progression, time-to-response,
time-to-chemotherapy (TTCT), and NGS biomarker analyses were
exploratory (see Supplementary Materials for definitions of clinical
endpoints). Other protocol-specified endpoints are not presented
here (21).
Statistical analyses
Although EGFR mutation subtype was a prespecified subgroup,
RELAYwas not powered for analysis of this or any other subgroup.HR
and 95% confidence intervals (CI) were estimated using an unstratified
Cox proportional hazards model. Kaplan–Meier estimation was used
to plot time-to-event data, as well as to provide summary statistics.
Differences between response rates and associated 95% CIs for treat-
ment arms by mutation subgroup were calculated using Fisher exact
method. Descriptive summary statistics were used for safety analyses.
Sankey diagrams were constructed to summarize post–study treat-
ment discontinuation therapy across both arms and to explore any
treatment patterns observed. Relationships between somatic gene
alterations and EGFR-activating mutation subgroup on PFS were
explored using interaction tests from the Cox regression model. Fisher
exact method compared mutation frequencies across treatment arms
within each EGFR mutation subgroup. Additional methodologic
details for the exploratory biomarker analyses are provided in the
Translational Relevance
Previous evidence suggests that in EGFR-mutated metastatic
non–small cell lung cancer (NSCLC), patients with ex21L858R
mutation have a poorer prognosis and response to treatment with
EGFR–tyrosine kinase inhibitor (TKI) monotherapy than patients
with ex19del mutation. Results from RELAY showed that combi-
nation of the antiangiogenic agent ramucirumab with EGFR-TKI
targeted therapy provided significant and similar clinical benefit for
both EGFR ex19del and ex21L858R NSCLC, suggesting that the
addition of an antiangiogenic agent may abrogate the differential
efficacy observed in ex21L858R patients compared with ex19del
patients when treated with EGFR-TKI monotherapy. These find-
ings may help clinicians provide a personalized treatment strategy
and allow treatment decisions to be made on a more rational basis.
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Supplementary Materials and Methods. SAS v9.4 and SAS VA v7.3
(SAS Institute) were used for all statistical analyses.
Results
Patients, EGFR testing, and baseline characteristics
In RELAY, 449 patients (intention-to-treat population) were ran-
domized between January 28, 2016 and February 1, 2018 to either
RAMþERL or PBOþERL treatment arms (Supplementary Fig. S1).
Two patients were excluded from this analysis as they were subse-
quently shown not to harbor an ex19del or ex21L858R mutation.
Thus, the total population for the efficacy analyses by EGFRmutation
subgroups was 447 patients [243 (54%) ex19del and 204 (46%)
ex21L858R]. The safety analyses excluded three of the 447 patients
who did not receive any study drug (one ex19del and two
ex21L858R patients); all were assigned to treatment with RAMþERL.
As of primary data cutoff (January 23, 2019), 63 ex19del (59%
RAMþERL, 41% PBOþERL) and 44 ex21L858R (61% RAMþERL,
39% PBOþERL) patients remained on study treatment (Supplemen-
tary Fig. S1).
Central tissue testing results corroborated the local EGFR testing
results, with 97% of centrally tested patients (305 of 316 evaluable
results) having an EGFR-activating mutation detected (53% ex19del
and 44% ex21L858R; ref. 19). In addition, 324 patients had evalu-
able baseline plasma NGS results, with ex19del and ex21L858R
mutations present at equivalent rates (50%; Supplementary Fig. S1).
Unless otherwise indicated, subsequent analyses for this report used
baseline EGFR-activating mutation status as determined by local
testing.
The majority of patients in each EGFR mutation subgroup,
regardless of treatment arm, were female, never smokers, had
similar median age, and an Eastern Cooperative Oncology Group
performance status of 0 (Table 2). Ex21L858R was more prevalent
than ex19del among patients of Asian race (83% vs. 72%) and
females (67% vs. 60%); bone metastases were more common in
patients with ex21L858R than with ex19del (34% vs. 26%). Other
baseline patient and disease characteristics were similar between
EGFR mutation subgroups.
Efficacy
With a median follow-up of 20.7 months (range, 0.1–35.4), PFS
treatment benefit with RAMþERL was similar between EGFR
mutation subgroups (Table 1; ref. 19). Improvements in median
PFS among patients receiving RAMþERL versus PBOþERL were
7.1 and 8.2 months for ex19del and ex21L858R subgroups, respec-
tively. One-year PFS rates for ex19del patients were 74% (95% CI,
64.1–80.8) for RAMþERL versus 54% (95% CI, 43.9–62.2) for
PBOþERL, and for ex21L858R patients were 70% (95% CI,
58.9–77.9) for RAMþERL versus 47% (95% CI, 37.0–57.1) for
PBOþERL (Fig. 1A; Table 1; ref. 19).
Irrespective of treatment arm, stable disease (SD)was reportedmore
frequently in ex21L858R patients (25%) than ex19del patients (15%),
whereas partial response (PR) was more prevalent in ex19del patients
(79%) than in ex21L858R patients (69%). Overall response rate (ORR)
was lower in ex21L858R patients (70%) than ex19del patients (81%),
with the lowest ORR observed in the ex21L858R subgroup treatedwith
PBOþERL (ex19del: RAMþERL 79%, PBOþERL 83%; ex21L858R:
RAMþERL 74%, PBOþERL 66%; Table 3; Supplementary Fig. S2).
Disease control rate was high (>90%) and similar in the ex19del and
ex21L858R subgroups (Table 3; Supplementary Fig. S2). The median
time-to-response for patients was similar (1.4–1.5 months) across
mutation subgroups and treatment arms (Table 3).
DOR analysis included fewer ex21L858R patients as SD was more
prevalent in this subgroup. For both mutation subgroups, DOR
favored the RAMþERL versus the PBOþERL arm (Fig. 1B). Relative
to the ex21L858R subgroup, the ex19del subgroup treated with
RAMþERL exhibited a numerically longer median DOR [18.2
(95% CI, 13.8–20.9) vs. 16.2 (95% CI, 12.5–20.1) months].














Sex, n (%) Female 146 (60) 136 (67) 74 (60) 72 (60) 66 (67) 70 (67)
Age in years, median (range) 63 (23–84) 66 (41–89) 64 (27–84) 63 (23–83) 67 (44–86) 66 (41–89)
Racea Asian 174 (72) 170 (83) 89 (72) 85 (71) 81 (82) 89 (85)
Caucasian 67 (28) 33 (16) 34 (28) 33 (28) 18 (18) 15 (14)
Smoking history, n (%) Never 144 (59) 127 (62) 71 (58) 73 (61) 61 (62) 66 (63)
ECOG performance status, n (%) 0 131 (54) 103 (51) 65 (53) 66 (55) 50 (51) 53 (51)
Disease classification, n (%) Primary metastatic 207 (85) 178 (87) 103 (84) 104 (87) 91 (92) 87 (83)
Recurrentmetastatic 36 (15) 26 (13) 20 (16) 16 (13) 8 (8) 18 (17)
Metastases sites, n (%) Lung 224 (92) 188 (92) 112 (91) 112 (93) 93 (94) 95 (91)
Lymph 152 (63) 127 (62) 78 (63) 74 (62) 64 (65) 63 (60)
Bone 63 (26) 69 (34) 35 (29) 28 (23) 33 (33) 36 (34)
Liver 26 (11) 19 (9) 11 (9) 15 (13) 10 (10) 9 (9)
Other 146 (60) 104 (51) 70 (57) 76 (63) 48 (49) 56 (53)
Number of metastatic sites 1 29 (12) 23 (11) 12 (10) 17 (14) 9 (9) 14 (13)
2 90 (37) 86 (42) 50 (41) 40 (33) 46 (47) 40 (38)
3 99 (41) 74 (36) 50 (41) 49 (41) 32 (32) 42 (40)
4 20 (8) 15 (7) 11 (9) 9 (8) 9 (9) 6 (6)
≥5 5 (2) 6 (3) 0 5 (4) 3 (3) 3 (3)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; n, number of patients per category; N, number of patients in population.
aPBOþERL arm included three Other: one Black or African American, one Missing (ex19del group), one American Indian or Alaska Native (ex21L858R group).
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The iOS data were immature as censoring rates were high (overall
censoring rate ¼ 82%; Table 3). The highest rate of death was
observed in the ex21L858R PBOþERL treatment arm [ex19del:
RAMþERL 17% (21 deaths), PBOþERL 13% (15); ex21L858R:
RAMþERL 16% (16), PBOþERL 26% (27)]. Two-year OS rates
were lowest for ex21L858R patients in the PBOþERL treatment
arm, whereas RAMþERL–treated patients with ex21L858R
reported a comparable 2-year OS rate to patients with ex19del
(Table 3).
To further evaluate the impact of treatment by baseline
EGFR mutation subgroups on other post–study treatment discon-
tinuation endpoints, PFS2 and TTCT were explored. PFS2 data were
immature (overall censoring rate ¼ 69%), with the lowest censoring
rate observed for ex21L858R patients receiving PBOþERL (58%),
indicating that most PFS2 events occurred in this subgroup.
Ex21L858R patients receiving RAMþERL continued to exhibit
improved benefit through PFS2 compared with those receiving
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Clinical endpoints by baseline activating EGFR mutation subgroup. A, Progression-free survival. Data from Nakagawa and colleagues (19). B, Duration
of response. C, Progression-free survival 2. D, Time-to-chemotherapy. Abbreviations: NE, not evaluable; NR, not reached; PD, progressive disease. (Continued
on the following page.)
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ex19del subgroup had similar PFS2 between treatment arms (HR ¼
0.926; 95% CI, 0.577–1.485). For TTCT, a treatment benefit for
RAMþERL versus PBOþERL patients was observed for the
ex21L858R subgroup (HR ¼ 0.554; 95% CI, 0.352–0.872; censoring
rate ¼ 61%; Fig. 1D). No difference between treatment arms was
observed for the ex19del subgroup (HR ¼ 1.034; 95% CI, 0.682–
1.567; censoring rate ¼ 63%).
Further analyses of PFS2 and TTCT both indicated a trend toward
predictive effect regardless of mutation type. This trend was preserved
upon adjusting for other factors via amultivariatemodel (interaction P
values: PFS2 ¼ 0.2100; TTCT ¼ 0.0443).
Exposure
Of those patients in the ex19del subgroup, 122 received RAMþERL
and 120 PBOþERL, and of those in the ex21L858R subgroup, 97
received RAMþERL and 105 PBOþERL (Table 3). In the ex19del
subgroup, among patients receiving RAMþERL, median (minimum–
maximum) duration of exposure to ramucirumab (excluding 37
patients still on treatment) was 12.4 (0.5–33.8)months and to erlotinib
15.2 (0.1–33.8)months. Among patients receiving PBOþERL,median
duration of exposure to placebo (excluding 26 patients still on treat-
ment) was 11.0 (0.5–35.4) months and to erlotinib 12.0 (0.4–35.5)
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receiving RAMþERL, the median duration of exposure to ramucir-
umab (excluding 27 patients still on treatment) was 12.7 (0.5–33.2)
months and to erlotinib 15.1 (0.0–33.0) months. Among patients
receiving PBOþERL, the median duration of exposure to placebo
(excluding 27 patients still on treatment) was 8.8 (0.5–35.0) months
and to erlotinib 10.4 (0.8–35.1) months (Table 3).
Safety
All patients reported at least one treatment-emergent AE (TEAE;
Supplementary Table S1). Overall, there were no clinically mean-
ingful differences in safety findings between the mutation sub-
groups, although, of note, any-grade hypertension was reported
with a ≥10% higher incidence in the ex21L858R subgroup than the
ex19del subgroup [50 patients (41%) vs. 50 patients (52%), respec-
tively; Supplementary Table S2]. Incidence of grade 3 or higher
TEAEs and serious AEs (SAE) was similar between ex19del and
ex21L858R subgroups (Supplementary Table S1). Study treatment
discontinuation rates due to AEs and SAEs were also similar
between EGFR mutation subgroups (AEs: RAMþERL 13% and
13% and PBOþERL 8% and 14%, ex19del vs. ex21L858R, respec-
tively; SAEs: RAMþERL 3% and 6% and PBOþERL 4% and 4%,
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123 34 (28)
120 35 (29) 85 (71) NR
89 (72) 33.1 (28.1–NR)
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Unstratified HR (95% CI): 0.600 (0.371–0.969)
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Median, months (95% CI)
Figure 1.
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study treatment occurred in two RAMþERL–treated patients with
an ex21L858R mutation (one death due to hemothorax was con-
sidered related, and the other death due to encephalitis influenza
was considered not related to study treatment; Supplementary
Table S1).
Clinical patterns of progression
Overall, frequencies of disease progression were similar by treat-
ment regardless of mutation type, with rates being lower for the
RAMþERL combination (ex19del: RAMþERL 46%, PBOþERL
65%; ex21L858R: RAMþERL 49%, PBOþERL 64%; Supplementary
Fig. S1). The majority of sites of progression were in the lung, followed
by pleura and lymph nodes, regardless of treatment arm and EGFR
mutation subgroup (Supplementary Fig. S3). CNS metastasis devel-
oped more frequently in patients with ex21L858R [6 patients in the
ex21L858R subgroup (2 patients and 4 patients in the RAMþERL and
PBOþERL arms, respectively) and 1 patient in the ex19del subgroup
(PBOþERL arm)]. The majority of patients had single-site progres-
sion; this was reported more frequently in ex21L858R patients (102
patients, 79%) comparedwith ex19del patients (91 patients, 62%). This
difference wasmostly driven by patients in the ex21L858R RAMþERL
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increase in size of a single preexisting tumor lesion, occurred in
approximately 50% of patients across treatment arms and EGFR
mutation subgroups. Metastatic progression, defined as development
of at least one new lesion, occurred in 52 patients (36%) versus 53
patients (41%) in the ex19del versus ex21L858R subgroups, respec-
tively (Supplementary Fig. S4).
Subsequent therapies
All study treatment was to be discontinued upon RECIST v1.1–
defined disease progression. At time of data cutoff, 37 (30%) and 26
(22%) ex19del patients and 27 (27%) and 17 (16%) ex21L858R
patients (RAMþERL vs. PBOþERL, respectively) were still on
study treatment. First subsequent therapy (FST) was received by
66 (54%) and 83 (69%) ex19del patients and 54 (55%) and 73 (70%)
ex21L858R patients (RAMþERL vs. PBOþERL, respectively; Sup-
plementary Table S3). Sankey diagrams depict the flow and patterns
of subsequent lines of treatment (Supplementary Fig. S5). For both
EGFR mutation groups, the most commonly used FST was an
EGFR-TKI, predominantly erlotinib, and to a lesser degree, osi-
mertinib, followed by platinum-based chemotherapy. Ex19del
patients treated with RAMþERL received erlotinib as FST (52%)
more frequently compared with PBOþERL patients (29%); for
ex21L858R patients, erlotinib as FST was received at similar rates
in RAMþERL (50%) and PBOþERL patients (42%). Osimertinib
was used more frequently as FST in ex19del patients treated with
PBOþERL (31%) compared with RAMþERL (14%); for ex21L858R
patients, osimertinib was received at similar rates in RAMþERL
(17%) and PBOþERL patients (12%). In ex21L858R, chemotherapy
was used as FST at similar rates in patients treated with RAMþERL
and PBOþERL (43% vs. 47%), whereas more patients treated with
PBOþERL than RAMþERL received chemotherapy as second
subsequent therapy (SST; 66% vs. 42%).
At time of data cutoff, approximately 35% of patients were still on
FST. Nearly one third of patients who received osimertinib as FST
remained on this therapy in both ex19del and ex21L858R subgroups,
regardless of prior study treatment (Supplementary Table S3). As SST,
osimertinib was most frequently used, regardless of prior study
treatment: 29 patients (39%) versus 16 patients (25%) in the ex19del
versus ex21L858R subgroups, respectively.
Exploratory biomarker analyses
NGS testing was performed to examine the somatic alteration
landscape by ex19del or ex21L858R subgroups to gain insights on
potential biological differences at baseline and mechanisms of
Table 3. Clinical outcomes by baseline EGFR-activating mutation subgroup and by treatment arms.
Ex19del Ex21L858R
RAMþERL PBOþERL RAMþERL PBOþERL
Duration of therapya
n 122 120 97 105
Ramucirumab/placebo
Event rates, n (%) 85 (70) 94 (78) 70 (72) 88 (84)
Censoring rates, n (%) 37 (30) 26 (22) 27 (28) 17 (16)
Median, months (95% CI) 12.4 (9.4–14.8) 11.0 (8.5–12.4) 12.7 (8.0–15.1) 8.8 (6.8–11.1)
Erlotinib
Event rates, n (%) 85 (70) 94 (78) 70 (72) 88 (84)
Censoring rates, n (%) 37 (30) 26 (22) 27 (28) 17 (16)
Median, months (95% CI) 15.2 (12.9–19.5) 12.0 (10.6–13.8) 15.1 (12.7–19.5) 10.4 (7.7–12.4)
Overall response rate
n 123 120 99 105
ORR, % (95% CI) 79 (72–86) 83 (76–89) 74 (65–82) 66 (57–75)
Disease control rate
n 123 120 99 105
DCR, % (95% CI) 96 (92–99) 96 (92–99) 95 (91–99) 95 (91–99)
Time-to-response
n 97 99 73 69
Median, months (95% CI) 1.4 (1.3–2.6) 1.4 (1.3–1.7) 1.5 (1.4–1.7) 1.4 (1.3–1.6)
Duration of response
n 97 99 73 69
Event rates, n (%) 53 (55) 75 (76) 48 (66) 53 (77)
Censoring rates, n (%) 44 (45) 24 (24) 25 (34) 16 (23)
Median, months (95% CI) 18.2 (13.8–20.9) 11.0 (9.7–12.3) 16.2 (12.5–20.1) 11.1 (9.7–12.7)
Hazard ratio (95% CI) 0.54 (0.38–0.77) 0.73 (0.49–1.08)
Interim OS
n 123 120 99 105
Event rates, n (%) 21 (17) 15 (13) 16 (16) 27 (26)
Censoring rates, n (%) 102 (83) 105 (88) 83 (84) 78 (74)
Median, months NR NR NR NR
Hazard ratio (95% CI) 1.44 (0.74–2.80) 0.61 (0.33–1.14)
1-year OS rate, % (95% CI) 94 (88–97) 94 (88–97) 92 (84–96) 93 (86–97)
2-year OS rate, % (95% CI) 83 (74–89) 87 (78–93) 84 (74–90) 71 (58–80)
Abbreviations: DCR, disease control rate; NR, not reached.
aDuration of therapy is censored at the last date of study treatment for patients who remain on study treatment (ex19del: n¼ 122 RAMþERL vs. 120 PBOþERL and
ex21L858R: n ¼ 97 RAMþERL vs. 105 PBOþERL patients).
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resistance. In 320 of the patients with at least one detectable somatic
gene alteration, EGFR-activating mutations [ex19del: 134 (41.9%);
ex21L858R: 121 (37.8%)] were detected at baseline by NGS (this
was 100% concordant with local EGFR testing results); 10% of
ex19del and 13% of ex21L858R patients did not have any additional
somatic gene alteration.
Concomitant gene alterations were widespread in both ex19del and
ex21L858R mutated patients with NSCLC. The most frequent genes
with co-occurring variants at baseline were TP53 and additional EGFR
variants (Supplementary Table S4), each with similar prevalence
regardless of EGFR-activating mutation subgroup (Fig. 2A). PIK3CA
was higher in ex19del patients andwas the only genewith co-occurring
A
Ex19del Ex21L858R
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Patients with TE comutation (%)
EGFR T790M 27.3 34.0 23.5 27.1
EGFR other 18.2 13.2 14.7 29.2
TP53 30.3 9.4 11.8 16.7
MET 6.1 3.8 5.9 10.4
KRAS 15.2 1.9 2.9 4.2
APC 9.1 3.8 5.9 2.1
BRAF 6.1 3.8 0 8.3
NF1 9.1 1.9 8.8 2.1
PIK3CA 3.0 1.9 0 12.5
BRCA2 0 1.9 5.9 6.3
ERBB2 3.0 1.9 2.9 6.3
FGFR2 6.1 3.8 2.9 2.1
ARID1A 3.0 3.8 2.9 2.1
KIT 6.1 0 2.9 2.1
PTEN 3.0 0 2.9 4.2
RB1 6.1 0 0 4.2
AR 3.0 0 0 4.2
CDK4 3.0 1.9 0 2.1
CDK6 3.0 0 0 4.2
MYC 0 0 2.9 4.2
SMAD4 3.0 0 0 4.2
CCND2 0 0 2.9 2.1
DDR2 3.0 0 0 2.1
ESR1 3.0 0 0 2.1
FGFR1 3.0 0 0 2.1
GNAS 3.0 0 2.9 0
MAP2K1 3.0 0 2.9 0
PDGFRA 3.0 0 0 2.1
B
*No EGFR T790M was identified at baseline.
Figure 2.
Guardant360 NGS detected somatic gene alterations at baseline or treatment emergent (TE), co-occurring with ex19del or ex21L858R, and impact on outcomes.
A, Baseline somatic gene alterations co-occurring with either ex19del or ex21L858R mutations as detected by Guardant360 NGS. B, Treatment-emergent somatic
gene alterations co-occurringwith either ex19del or ex21L858Rmutations in patientswith Guardant360NGS–positive results andwho had disease progression at the
post–study treatment discontinuation follow-up visit. Analysis focused on those patients with at least one alteration detectable both at baseline and at disease
progression; this approach, in part, controls for potential differences in tumor shedding. Abbreviations: CNA, copy-number alterations; SNV, single-nucleotide
variants; wt, wild-type.
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variants having differential prevalence (>5%) by EGFR-activating
mutation subgroup. In patients with TP53 comutation, RAMþERL
demonstrated a superior PFS treatment benefit versus PBOþERL
in both ex19del and ex21L858R subgroups (Supplementary Fig. S6).
In TP53 wild-type patients, the benefit of RAMþERL on PFS
appeared more pronounced in the ex21L858R subgroup than the
ex19del subgroup.
Treatment-emergent gene alterations co-occurring with either
ex19del or ex21L858R mutations are presented in Fig. 2B. EGFR
T790M was the most prevalent treatment-emergent gene alteration
in both EGFR mutation subgroups. Other EGFR variants and
TP53 were the second most prevalent comutated genes at disease
progression, and prevalence varied by EGFR mutation sub-
group and treatment arm. Other treatment-emergent EGFR var-
iants were observed at highest prevalence (29.2%) in ex21L858R
PBOþERL–treated patients, and TP53 variants were highest
(30.3%) in ex19del RAMþERL–treated patients. The only genes
with co-occurring variants having differential prevalence (>10%) by
EGFR-activating mutation subgroup treatment arm were KRAS
(higher with RAMþERL in ex19del patients) and PIK3CA (higher
with PBOþERL in ex21L858R patients).
T790M rates at 30-day follow-up were similar across the two
mutation subgroups and treatment arms (Supplementary Fig. S7).
Among ex19del patients, emergence of T790M appeared to be delayed
in those receiving RAMþERL. T790M was only observed in ex19del
patients receiving RAMþERLwho progressed after completing at least
12 cycles of treatment compared with PBOþERL, where emergence
was seen in patients who progressed after at least four cycles of
treatment. In ex21L858R patients, T790M appeared to emerge in
patients after at least four cycles of treatment, independent of treat-
ment received. Among PBOþERL–treated patients with post-
progression TP53 detected at the 30-day follow-up, newly emergent
TP53 alterations were detected as early as four cycles of treatment,
independent of ex19del or ex21L858R (Supplementary Fig. S8). For
RAMþERL–treated patients, emergence of TP53 was observed in
patients who completed at least four cycles for ex19del, and at least
12 cycles of treatment for ex21L858R.
Discussion
The expanding armamentarium of effective treatments for
EGFR-mutated NSCLC highlights the importance of fully under-
standing each treatment regimen so that therapy can be tailored to
individual patient and disease characteristics. There is a growing
body of evidence that patients with an ex21L858R mutation have a
poorer prognosis and response to treatment with EGFR-TKIs than
patients with ex19del mutation.
In RELAY, RAMþERL showed consistent treatment benefit among
patients with ex19del or ex21L858R,whereas treatment outcomeswere
worse with ex21L858R than ex19del in those receiving PBOþERL.
Evidence suggests that different subtypes of EGFRmutation may vary
in their clinical and pathologic correlations (22, 23). In RELAY, patient
and disease characteristics at baseline, including NGS-determined
comutations, were similar between EGFR mutation subgroups with
the exception of ex21L858R being more prevalent among females and
Asian patients. So, the subgroup of ex21L858R patients did not appear
to be enriched with more poor prognostic features than the subgroup
of ex19del patients.
Patterns of progression were reported at similar rates between the
two mutation subgroups, with the exception of CNS metastases being
more frequently reported as site of first progression in patients with
ex21L858R. This could indicate a more aggressive phenotype of
ex21L858R tumors, although the small number of events limits the
strength of this observation.
The magnitude of PFS benefit with RAMþERL observed for
patients with ex21L858R was similar to that of RAMþERL–treated
patients with ex19del (19). RAMþERL–treated patients with
ex21L858R also had treatment benefits in ORR, DOR, PFS2, TTCT,
and iOS; the worst outcomes were observed in PBOþERL–treated
patients with ex21L858R. Analyses evaluating TTCT showed that,
despite high censoring, use of chemotherapy was significantly delayed
with RAMþERL versus PBOþERL in ex21L858R patients but not
ex19del patients. Subsequent therapies received and presence of
treatment-emergent T790M and/or TP53 mutations may have had
a role in the TTCT results observed. Although a predictive effect of
mutation type on PFS was not apparent, further analyses of PFS2 and
TTCT both indicated a trend toward predictive effect regardless of
mutation type on benefit of RAMþERL. Given limited event counts
and data immaturity for post-progression outcomes and ex19del being
more common in Western patients, who were underrepresented in
RELAY (28% were Caucasian), the results are to be interpreted with
caution. In general, there were no meaningful differences in the safety
profiles of RAMþERL by activating mutation subgroups.
The underlying reasons for the differential efficacy between ex19del
and ex21L858R mutation subtypes being treated with EGFR-TKI
monotherapy are not fully understood (12). One suggestion is that
ex21L858R is less efficiently inhibited by EGFR-TKIs than ex19del.
In vitro studies have shown that gefitinib inhibited EGFR phos-
phorylation, ameasure of kinase inhibitor potency, to a lesser degree in
cancer cells with ex21L858R than with ex19del mutation (24), whereas
kinetic analysis has demonstrated ex21L858R to be less sensitive than
ex19del to erlotinib inhibition (25). These findings offer some rationale
for the difference in outcomes between the EGFR mutation subtypes
when treated with single-agent EGFR-TKI.
Interestingly, a consistent PFS benefit between ex19del and
ex21L858R groups has also been reported in patients receiving erlo-
tinib and bevacizumab (Table 1; refs. 16–18), and meta-analyses of
EGFR-TKI and antiangiogenic agent combinations (26, 27), suggest-
ing that addition of an antiangiogenic agent appears to abrogate the
differential efficacy observed in ex21L858R compared with ex19del
patients when treated with EGFR-TKI monotherapy. Unfortunately, a
comprehensive understanding of the underlying biological mechan-
isms that could support the clinical observations with ex19del and
ex21L858R mutations is currently lacking, and so it is unknown if this
is related to dual EGFR/VEGF pathway inhibition. On the basis of the
observation that ex21L858R patients receiving high-dose EGFR-
TKI treatment have improved outcomes compared with those
receiving standard-dose EGFR-TKI (28), it could be hypothesized
that addition of an antiangiogenic agent might lead to increased and
sustained high concentrations and uptake of EGFR-TKIs by nor-
malizing blood flow through tumor blood vessels (25, 29, 30).
Further preclinical studies are needed to elucidate biological differ-
ences between ex19del and ex21L858R mutations.
The wide range of preexisting co-occurring and treatment-
emergent genetic alterations underscore the fact that EGFR-mutant
lung cancer is a heterogeneous disease, which might contribute to the
differential sensitivity and varied responses achieved upon EGFR-TKI
treatment. Concurrent TP53 mutations have been shown to be a
negative prognostic factor and associated with poorer outcomes in
patients treated with EGFR-TKIs (31). A role for TP53 in angiogenesis
has also been established, and multiple studies have suggested
that presence of a TP53 mutation is associated with VEGF pathway
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upregulation and may be predictive of clinical sensitivity to antian-
giogenic therapies in several tumor types (32–35). In RELAY, the
prevalence of TP53 mutations at baseline (43% vs. 43%) and at time
of disease progression (17% vs. 15%) was similar in ex19del and
ex21L858R subgroups. Baseline TP53 mutation was associated with
superior outcomes for RAMþERL in both ex19del and ex21L858R
subgroups, whereas in TP53 wild-type patients, the benefit of
RAMþERL appeared more pronounced in the ex21L858R than
the ex19del subgroup. At disease progression, treatment-emergent
TP53 variants were most prevalent in ex19del RAMþERL–treated
patients, and additional experimentation is needed to determine the
relevance and if it is related to mechanisms of acquired resistance.
Further, treatment-emergent T790M as a mechanism of resis-
tance is reported to occur more frequently in ex19del than
ex21L858R patients (36, 37). In RELAY, no T790M was identified
in circulating tumor DNA plasma samples at baseline; however,
T790M was, as expected, the most prevalent genetic alteration post–
study treatment discontinuation. EGFR T790M mutation rate at
progression was similar between treatment arms and by mutation
type (Supplementary Fig. S1), suggesting that addition of ramucir-
umab to erlotinib does not alter the T790M resistance mechanism
pathway. In ex19del patients, the emergence of T790M may be
delayed in those receiving RAMþERL, whereas this was not
observed in ex21L858R patients. However, as median PFS times
were similar for RAMþERL–treated ex19del and ex21L858R
patients, the difference in the timing of T790M emergence does
not appear to contribute to the enhanced benefit observed in
ex21L858R patients upon addition of ramucirumab to erlotinib
treatment. Subsequent treatment with an agent that targets the
EGFR T790M mutation, such as osimertinib, could further delay
disease progression and TTCT for the considerable proportion of
patients who acquire the EGFR T790M mutation. Indeed, in this
study, osimertinib was used as post-discontinuation therapy across
subsequent lines of therapy (Supplementary Table S3).
We acknowledge a number of limitations in our study. RELAY
was not sufficiently powered for subgroup analyses of ex19del
and ex21L858R, although these were prespecified, and a random-
ization factor. In addition, results of the exploratory biomarker
analyses should be viewed with caution because of low patient
numbers at varying time points. All NGS analyses were performed
on plasma samples only. As a consequence, some important
mechanisms of resistance, such as histological transformation and
copy-number alterations (which are more difficult to capture in
plasma) have not been explored optimally. Differences in preva-
lence and timing of treatment-emergent mutations between treat-
ment arms (e.g., delay in emergence of T790M or TP53) are
possibly biased toward early progressors, as patients for whom no
post-discontinuation plasma is available yet are those still benefit-
ing from treatment. The final NGS analysis at time of OS maturity
should provide a clearer understanding of the impact of treatment-
emergent alterations.
Analyses of the EGFR mutation subgroups in RELAY is for the
purposes of hypothesis generation and reflects an attempt to better
understand the heterogeneity of the disease. We believe that under-
standing the potential impact of differences between ex19del and
ex21L858R patients is clinically relevant and could have several
potentially significant clinical and research implications. Findings will
be useful for counseling patients and could help inform treatment
decisions. Our data demonstrate that ex19del and ex21L8585R muta-
tions have different prognostic and predictive roles dependent on the
therapy used and are therefore an important stratification factor in
clinical trials. Further drug development, particularly for tumors with
ex21L858R that have a poorer response to EGFR-TKI monotherapy,
remains important. Further prospective studies are warranted to
confirm the role of combined EGFR-TKI and antiangiogenic treat-
ment in patients with ex21L858R mutations. The recently started
WJOG phase III study of erlotinib plus ramucirumab versus osimer-
tinib in advanced NSCLC with EGFR ex21L858R mutation
(REVOL858R; jRCTs051200142) will help address this question.
In summary, RELAY demonstrates that RAMþERL has signif-
icant clinical benefit for both EGFR ex19del and ex21L858R
NSCLC, supporting this regimen as suitable for patients with either
of these EGFR mutation types. However, as ex21L858R-positive
patients historically have poorer outcomes relative to ex19del in
response to EGFR-TKI monotherapies, this subgroup of EGFR-
mutant NSCLC may be a higher priority for addition of an anti-
angiogenic to an EGFR-TKI. Our findings provide evidence that
patients with EGFR ex19del and ex21L8585R mutations do not have
a heterogeneous response to EGFR-TKI targeted therapy when
combined with ramucirumab. These findings may help clinicians
provide a personalized treatment strategy and allow treatment
decisions to be made on a more rational basis.
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